

## Prevalence, antimicrobial susceptibility pattern and risk factors of MRSA isolated from clinical specimens among military patients at 48 Medical Compound in Sana'a city-Yemen

### Abstract

Methicillin-resistant strains of *S. aureus* evolved in the 1970s and have troubled hospitals worldwide with persistent infections in patients. The objectives of this study were to determine the prevalence, antimicrobial susceptibility pattern and risk factors of MRSA isolated from clinical specimens among military patients at 48 Medical Compound in Sana'a city - Yemen. The study included 233 patients of whom suffering from *Staphylococcus aureus* infections. Specimens and data collected from November 2016 to November 2017. Standard methods of isolation and identifications were used to isolate bacteria in pours culture then *Staphylococcus aureus* were identifying using standard cultural techniques. MRSA was determined by the disc diffusion method to oxacillin and antimicrobial susceptibility testing was performed by the disc diffusion method for selected antibiotics. The prevalence rate of MRSA was 19.3% and there was significant association between MRSA and older age patients, and surgical site infections. There was higher rate of antibiotics resistant for tested antibiotics in MRSA isolates comparing with lower rate of antibiotics resistant in MSSA. 60% of the MRSA isolates were resistant to vancomycin. They were also susceptible to erythromycin and rifampicin (100%), but showed resistance to Cotrimoxazole and Gentamycine. In conclusion, the emergence of *S. aureus* isolates resistant to vancomycin and other wide range of antibiotics have raised MRSA in Yemen into a multi-drug-resistant ‘Superbug’, making it more and more dangerous than ever in our hospital environments. Regular surveillance of hospital associated infections and monitoring antibiotic sensitivity pattern and strict drug policy for antibiotics used within and outside the hospital environments are recommend.

**Keywords:** MRSA, MSSA, MDR, Superbug, Sana'a city, Yemen

### Introduction

*Staphylococcus aureus* (*S.aureus*) is a bacterium of significant importance because of its ability to cause a wide range of diseases and capacity to adapt to diverse environmental forms.<sup>1</sup> The organism colonizes skin, skin glands and mucous membrane, causing infections both in human and animals such as rashes, inflammations of bones and the meninges as well as septicaemia.<sup>2</sup> At present, the majority of *S. aureus* strains are resistant to most penicillin derivatives and ordinary antimicrobial agents like drugs from the family of aminoglycosides, macrolides, chloramphenicol, tetracyclines and fluoroquinolones.<sup>3</sup> The global spread of MRSA constitutes one of the most serious contemporary challenges to the treatment of hospital-acquired infections.<sup>4</sup> MRSA carries a uniquely effective antibiotic resistance mechanism that can protect the microorganisms against all members of  $\beta$ -lactam antibiotics. This makes infections caused by these pathogens very difficult to manage and costly to treat.<sup>5,6</sup>

The objectives of this study were to determine the prevalence, antimicrobial susceptibility pattern and risk factors of MRSA isolated from clinical specimens among military patients at 48 Medical Compound in Sana'a city – Yemen

### Subjects and Methods

#### Ethical Consideration

Ethical clearance for the study was taken from the Faculty of Medicine and Health Sciences Research Review Committee. A written permission was also taken from the administrative Manager of the 48 Medical Compound, Sana'a city, Yemen. Informed Consent was taken from the patients before the questionnaire was filled.

## Survey procedure and Laboratory Analysis

This study was conducted during a period of one year, starting in November 2016 and ending in November 2017 at 48 Medical compounds in Sana'a city-Yemen. All clinical specimens were received and collected by laboratory department of the hospital. 233 isolates of *S. aureus* were isolated from all age groups of out- or inpatients hospitalized in different wards. Clinical specimens were taken from various body sites of infection including blood, wound, sputum, urine and others. Clinical and demographic data were collected for all participants' patients. Clinical specimens were collected using standard collection techniques<sup>7, 8</sup>, and inoculated on appropriate bacteriological media, including Blood agar, Chocolate agar, Thioglycollate, Mac-Conkey Agar Media. The plates were incubated aerobically at 37 °C for 18–24 hours. The blood cultures were performed using an automated blood culture system, followed by bacterial growth inspection. The identification of isolates was made according to standard methods<sup>9</sup> for any potential clinically significant growth appear on the culture media on the base of quantity, feature of growth, source and site of specimens. The primary identification was made with basic microbiological methods using colony morphology, Gram staining, catalase and coagulase tests.<sup>7</sup> **Antibiotic Resistance Phenotypes (Methicillin/Oxacillin susceptibility testing):** All the *Staphylococcus aureus* isolates were tested for the susceptibility to 5 µg Methicillin disc and 1 µg Oxacillin disc provided by Difco using the disk diffusion method as described by NCCLS. The resistance breakpoints were  $\geq 14$  mm to  $\leq 10$  mm for 5 µg Methicillin, and  $\geq 12$  mm to  $\leq 10$  mm for 1 µg Oxacillin. The ability of other antibiotic disc to inhibit MRSA or MSSA were estimated according to the guidelines provided by NCCLS using commercially available discs which include: azithromycine (AZM, 15ug), chloramphenicol (C, 30ug), gentamycine (GN, 10ug), trimethoprim-sulfamethoxazole (SXT, 1,25/23,75ug), Oxacillin (OX, 1ug), erythromycin (E, 15ug), cefoxitin (FOX, 30ug), nitrofurantoin (NIT, 300ug), tetracycline (T, 30ug), teicoplanin (TE, 30ug), clindamycin (CC, 2ug), rifampicin (RA, 5ug), ciprofloxacin (5 µg, Ci), vancomycin (V, 30ug) and others listed in table 4.

### Data analysis

The analysis of data was done by Epi Info version 6 statistical program (CDC, Atlanta, USA), where the chi-square ( $\chi^2$ ) and probability value ( $p$ ) was calculated for the test of significance. In addition, Odd's ratio (OR), confidence interval (CI) were added to estimate the risk factors of contracting MRSA.

### Results

Tables 1, 2, 3 show the prevalence of MSSA and MRSA among isolated coagulase positive (*S. aureus*), the potential associated factors of MRSA in patients with *S. aureus* infection and the association between prevalence of MRSA and type of hospital wards. Also, the susceptibility pattern of *S. aureus* strains is presented in table 4. The prevalence rate of MRSA was 19.3% and there was significant association between MRSA and older age patients, and surgical site infections. There was higher rate of antibiotics resistant for tested antibiotics in MRSA isolates comparing with lower rate of antibiotics resistant in MSSA. Also, 60% of the MRSA isolates were resistant to vancomycin. They were also susceptible to erythromycin and rifampicin (100%), but showed resistance to Cotrimoxazole and Gentamycine.

### Discussion

We detected MRSA in 19.3% of all *staphylococcus aureus* isolates (table 1). Our result is lower than that reported from USA in which MRSA was isolated from 59% of patients with skin and soft tissue infections.<sup>10</sup> Also our 19.3% MRSA of all *staphylococcus aureus* isolates is lower than that reported from Yemen in previous reports in which MRSA was isolated from 55% of HCWs in Taiz city, Yemen<sup>11</sup> and extremely low from that reported by Al-Baidani *et al*,<sup>12</sup> among HCWs in Hodeida city, Yemen in which the MRSA rate was 86%. In addition, the prevalence of MRSA among our inpatients (HA-MRSA) was 19.4% roughly similar to 19.2% among

outpatients (CA-MRSA) (table .2). Prolonged hospital stays, indiscriminate use of antibiotics, lack of awareness, and receipt of antibiotics before coming to the hospital are some of the possible predisposing factors of MRSA emergence in the hospital and community. Our result is different from that reported from USA in which high rate of MRSA was occurred in hospital acquired *S. aureus* infections (HA-MRSA) (59%), than in community acquired infection *S. aureus* (17%).<sup>13</sup> This variation can be explained by that the biology of CA-MRSA appears to differ from that of HA-MRSA and CA-Methicillin-susceptible *S. aureus* (MSSA), perhaps allowing CA-MRSA to cause disease other than that expected from MSSA.<sup>14,15</sup> As HA-MRSA emerged, it likely did not merely replace HA-MSSA but led to an overall increase in *S. aureus* infections in healthcare settings.<sup>16,17</sup> In addition nearly all the researchers say the same thing that in-patients and out-patients have higher *S. aureus*/MRSA infections than *S. aureus* / MSSA because of wide spread of MRSA in community and hospitals environment.<sup>17, 18,19</sup>

When we considered age as risk factor of MRSA in our study, the highest incidence of MRSA in our cases were in age groups of > median (24 years). The risk age group of in-patients and out-patients in our study was different from that reported previously in several studies in which roughly equal rates of MRSA in the different age groups.<sup>20</sup> In our study when we considered the association between prevalence of MRSA and sites of infections (type of clinical specimens), the highest prevalence MRSA was 33.3% in surgical site infection (SSI) with associated odds ratio equal to 2.2 ( $P \geq 0.05$ ) (table 2). The general pattern of MRSA infections in this study is not different from that worldwide in which in MRSA in surgical site infection (SSI) was one of the major diagnosis infections by MRSA.<sup>20</sup>

We carried this study because of the knowledge of MRSA prevalence and the current antimicrobial profile is necessary in selection of appropriate empirical treatment of these infections and control of MRSA in hospitals is essential. In our study vancomycin resistant was 40% in isolated MRSA. This result is different from that reported in Asian countries in which the rate of vancomycin resistant was not more than 10%.<sup>21</sup> Also the incidence of VRSA in the Asian countries has been documented by Kaleem *et al*,<sup>22</sup> in Pakistan to be 3.3% , 6% in India, by Sonavane and Mathur<sup>23</sup>, 7.5% in Iran by Mehdinejad *et al*,<sup>24</sup> and 9% in Jordan by Al-Zoubi *et al*,<sup>3</sup>

The results of our study shows a higher rate of resistant of MRSA comparing with a study carried out at India in 2009 which showed variable susceptibility pattern with high resistance rates to tetracycline (82%), clindamycin (79%), and cotrimoxazole (59%), while in our study all MRSA were sensitive to rifampicin different to 50% of rifampicin resistant in India.<sup>25</sup> On other hand resistance to chloramphenicol (50%) and naldixic acid (50%) was lower than Indian studies in which resistance to chloramphenicol was 10% and naldixic acid was 9%.<sup>25</sup> Studies carried out at by Kishore *et al*,<sup>26</sup> in India, by Kaleem *et al*,<sup>22</sup> in Pakistani and by Al-Zoubi *et al*,<sup>3</sup> in Jordan showed that less than 10% of MRSA isolates were sensitive to Macrolides, whereas 38% of isolates were found to be sensitive in our study. In our study 100% of the MRSA isolates were sensitive to ciprofloxacin which is harmonized with the results of India , Pakistani, Iranian and Jordan studies in which ciprofloxacin also found to be 100% sensitive to all MRSA isolates.<sup>3,22,26, 27</sup> Effective antimicrobial activity as well as cost effectiveness should be considered in drugs prescribed for MRSA infections. Oral dosing options for antibiotics can allow earlier discharge of hospitalized patients and minimize the chances of VRSA emergence. Good hospital infection control measures prove to be the main stay against these infections because antibiotics can never be an effective alternative to good medical practice. Also, medium sensitivity percentages were found to gentamycine, trimethoprim-sulfamethoxazole and tetracycline (Table 4). Different sensitivity percentages have been reported to these three antibiotics worldwide<sup>28, 29, 30</sup> These differences might be due to prolonged antibiotic treatment, age, type of infection and geographical variation.

## Conclusions

In conclusion, the results of this study showed the importance of regular surveillance of hospital associated infections including monitoring antibiotic sensitivity pattern and strict drug policy for antibiotics used within and outside the hospital environments. Moreover, *in-vitro* susceptibility testing of every isolate of MRSA in the clinical laboratories may be helpful for reducing the incidence of these infections.

## Acknowledgments:

Authors acknowledge the support of Sana'a University and 48 Medical compounds , Yemen.

## Conflict of interest:

"No conflict of interest associated with this work".

## References

- 1-Lowy FD. *Staphylococcus aureus* infections. N Engl J Med 1998; 339(8):520-532.
- 2-Aklilu E, Zunita Z, Hassan L, Chen HC. Phenotypic and genotypic characterization of Methicillin-resistant *Staphylococcus aureus* (MRSA) isolated from dogs and cats at University Veterinary Hospital, University Putra Malaysia. Trop. Biomed. 2010; 27(3): 483-492.
- 3- Al-Zoubi, MS, Ibrahim Ali Al-Tayyar, Emad Hussein, *et al.* Antimicrobial susceptibility pattern of *Staphylococcus aureus* isolated from clinical specimens in Northern area of Jordan. Iran J Microbiol 2015; 7(5): 265–272.
- 4-Szczepanik A, Koziol-Montewka M, Al-Doori Z, Morrison D, Kaczor D. Spread of a single multi-resistant methicillin-resistant *Staphylococcus aureus* clone carrying a variant of staphylococcal cassette chromo-some mec type III isolated in a university hospital. Eur J Clin Microbiol Infect Dis 2007. 26: 29– 35.
- 5-Hiramatsu K, Katayama Y, Yuzawa H, Ito T. Molecular genetics of methicillin-resistant *Staphylococcus aureus*. Int J Med Microbiol 2002; 292: 67– 74.
- 6-Aires de Sousa M, de Lencastre H. Bridges from hospitals to the laboratory: genetic portraits of Methicillin-resistant *Staphylococcus aureus* clones. FEMS Immunol Med Microbiol 2004. 8; 40: 101– 11.
- 7-Cheesbrough MC. District Laboratory Practice in Tropical Countries. 1st Edn, Cambridge University Press, Cambridge 2006, UK.
- 8-CLSI (Clinical and Laboratory Standards Institute). Performance Standards for Antimicrobia Susceptibility Testing: Nineteenth Informational Supplement. CLSI document M100–S19; 2009.
- 9-Layer F, Ghebremedhin B, Moder KA, Konig W, Konig B. Comparative study using various methods for identification of *Staphylococcus* species in clinical specimens. J Clin Microbiol 2006. 44: 2824– 2830.
- 10-Krishnadasan A, *et al.* Methicillin-resistant *S. aureus* infections among patients in the emergency department. N Engl J Med. 2006; 355:666–74.
- 11-Abdel Monem, M.O. Nasal Carriage of *Staphylococcus aureus* among Healthcare Workers in Althawra Hospital, Taiz City, Republic of Yemen. Australian Journal of Basic and Applied Sciences 2012; 6(7): 417-424.
- 12-Al-Baidani AR, El-Shouny WA and Shawa TM. Antibiotic susceptibility of MRSA in three hospitals at Hodeida city Yemen. Globle J Pharma 2011; 5(2):106-111.
- 13-Fridkin SK, Hageman JC, Morrison M, Sanza LT, Como-Sabetti K, Jernigan JA, *et al.* Methicillin-resistant *Staphylococcus aureus* disease in three communities. N Engl J Med. 2005;352:1436–44. Erratum in: N Engl J Med 2005;352:2362.
- 14-Askarian M, Zeinazadeh A, Japoni A, *et al.*, 2009. Prevalence of nasal carriage o Methicillin resistance *Staphylococcus aureus* and its antibiotic susceptibility pattern in healthcare workers at Namazi Hospital, Shiraz, Iran. Int J Infect Dis 2009; 13:e241–e247.
- 15- Mahalingam U, Thirunvukarasu T, Muruganathan K. Methicillin resistant *Staphylococcus aureus* among nurses in a tertiary care hospital in Sri Lanka. Ceylon Medical Journal. 2014;S9:63–65.



- 16-Elie-Turenne MC, *et.al.* Prevalence and characteristics of *Staphylococcus aureus* colonization among healthcare professionals in an urban teaching hospital. *Infection Control and Hospital Epidemiology* 2010; 31:S74–S80
- 17- Radhakrishna M, D'Souza M, Kotigadde S, Vishwas-Saralaya K, Shashidar-Kotian M. Prevalence of methicillin resistant *Staphylococcus aureus* carriage amongst health care workers of critical care units in Kasturba Medical College Hospital, Mangalore, India. *Journal of Clinical and Diagnostic Research*. 2013;7(12):2697–2700.
- 18-Shibabaw A, Abebe T, Mihret A. Nasal carriage rate of methicillin-resistant *Staphylococcus aureus* among Dessie Referral hospital health care workers; Dessie Northeast, Ethiopia. *Antimicrobial Resistance and Infection Control* 2013; 2:25.
- 19-Iyer A, Kumosani T, Azhar E, Barbour E, Harakeh S. High incidence rate of methicillin-resistant *Staphylococcus aureus* among healthcare workers in Saudi Arabia. *J Infect Dev Ctnes*. 2014;8(3):372–378.
- 20-Tacconelli E. *et al* . "Does antibiotic exposure increase the risk of methicillin-resistant *Staphylococcus aureus* (MRSA) isolation? A systematic review and meta-analysis". *J Antimicrob Chemother* 2008; 61 (1): 26–38.
- 21-Mehmood A, Butt T, Usman M. A study on MRSA isolates to detect reduced susceptibility to vancomycin: A preliminary report. *Infect Dis J* 2007; 16:102–104.
- 22-Kaleem F, *et al.* Sensitivity pattern of methicillin resistant *Staphylococcus aureus* isolated from patients admitted in a tertiary care hospital of Pakistan. *Iran J Microbiol* 2010; 2(3): 143–146.
- 23-Sonavane A, Mathur M. Screening for vancomycin intermediate-resistant *Staphylococcus aureus* among clinical isolates of MRSA. *Indian J Med Microbiol* 2007;25:79–80.
- 24-Mehdinejad M, Sheikh AF, Jolodar A. Study of methicillin resistance in *Staphylococcus aureus* and species of coagulase negative Staphylococci isolated from various clinical specimens. *Pak J Med Sci*. 2008;24:719–24.
- 25-Idrees F, Jabeen K, Khan MS, Zafar A. Antimicrobial resistance profile of methicillin resistant *staphylococcal aureus* from skin and soft tissue isolates. *J Pak Med Assoc* 2009; 59:266–269.
- 26-Kishore S Deepika Verma, and ME Siddique. Comparison of In-vitro Activities of Linezolid and Vancomycin against *Staphylococcus aureus* Isolated from A Tertiary Care Hospital. *J Clin Diagn Res*. 2014; 8(5): DC12–DC15.
- 27-Fatholahzadeh B, Emaneini M, Gilbert G, *et al.* Staphylococcal Cassette Chromosome *mec* (SCC*mec*) Analysis and Antimicrobial Susceptibility Patterns of Methicillin-Resistant *Staphylococcus aureus* (MRSA) Isolates in Tehran, Iran. *Microb Drug Resist* 2008; 14: 217-220.
- 28-Rajaduraipandi K, Mani KR, Panneerselvam K, Mani M, Bhaskar M, Manikandan P. Prevalence and antimicrobial susceptibility pattern of methicillin resistant *Staphylococcus aureus*: a multicentre study. *Indian I Med Microbiol* 2006. 24: 34–38.
- 29-Hafeez R, C A, Aslam M. Prevalence and Antimicrobial Susceptibility of Methicillin Resistant *Staphylococcus aureus* (MRSA). *IJP* 2004; 2(1):10-15.
- 30-Babakir-Mina M, Othman N, Najmuldeen HH, *et al.* Antibiotic susceptibility of vancomycin and nitrofurantoin in *Staphylococcus aureus* isolated from burnt patients in Sulaimaniyah, Iraqi Kurdistan. *The new microbiologica*. 2012; 35: 439– 446.

**Table 1 :** The prevalence of MSSA and MRSA among isolated coagulase positive (*S. aureus*) in Sana'a city, 2017

Organisms	Number	Percentage
MSSA	188	80.7
MRSA	45	19.3
<b>Total <i>Staphylococcus aureus</i></b>	<b>233</b>	<b>100</b>

**Table 2:** The potential associated risk factors of MRSA in patients with *S.aureus* infection in Sana'a city, 2017

Factors	MRSA		MSSA		OR	CI	$\chi^2$	p
	No.	%	No.	%				
In-patients n=103	20	19.4	83	80.6	1.0	0.5-1.97	0.001	0.97
Out-patients n=130	25	19.2	105	80.8	0.98	0.5-1.9	0.001	0.97
Age Median (24 years)								
<24 years n=104	13	12.5	89	85.6	0.45	0.23-0.9	5	0.02
>24 years n=129	32	24.8	99	76.7	2.2	1.1-4.5	5	0.02
Clinical specimens								
Surgical wound pus n=39	9	23.1	30	76.9	1.3	0.6-3.2	0.6	0.43
Nonsurgical wounds pus n=77	13	16.9	64	83.1	0.78	0.36-1.6	0.43	0.51
Pleural fluid n=5	1	20	4	80	1.04	0.11-9.5	0.002	0.96
Sputum n=23	3	13	20	87	0.6	0.17-2.1	0.64	0.42
Surgical site infections (SSI) Wound and pus n=21	7	33.3	14	66.7	2.3	1.0-6	3.9	0.05
Urine culture n=41	6	14.6	35	85.4	0.67	0.26-1.7	0.69	0.4
Bone pus n=27	6	22.2	21	77.8	1.2	0.46-3.2	0.16	0.68

OR Odds ratio >1 (at risk)  
 CI Confidence intervals  
 $\chi^2$  Chi-square  $\geq 3.9$  (significant)  
 p Probability value  $\leq 0.05$  (significant)

**Table 3:** The association between prevalence of MRSA and type of hospital wards in Sana'a city.

In-patients Wards	MRSA		MSSA		OR	CI	$\chi^2$	p v
	No.	%	No.	%				
<b>Orthopedic ward</b> n=34 (33%)	7	20.6	27	79.4	1.1	0.39-3.1	0.031	0.86
<b>Urology wards</b> n=14 (13.5%)	4	28.6	10	71.4	1.5	0.45-5.1	0.37	0.59
<b>Internal Medical wards</b> n=7 (6.8%)	1	14.3	6	85.7	0.67	0.07-5.9	0.12	0.72
<b>Surgical wards</b> n=48 (46.6%)	8	16.7	40	83.3	0.56	0.2-1.5	1.3	0.25

OR Odds ratio >1 (at risk)

CI Confidence intervals  
 $\chi^2$  Chi-square  $\geq 3.9$  (significant)  
 p Probability value  $\leq 0.05$  (significant)

**Table 4:** The antibiotic sensitivity for isolated MRSA and MSSA for tested antibiotics in Sana'a city.

Antibiotics	MRSA n=45		MSSA n=188	
	% Sensitive	% Resistant	% Sensitive	% Resistant
<b>Azithromycin</b>	66.7	33.3	60.9	39.1
<b>Carbincillin</b>	0	100	100	0
<b>Cefotaxime</b>	25	75	61	39
<b>Cefepime</b>	44.4	55.6	65.6	34.4
<b>Ceftazidime</b>	50	50	50	50
<b>Ceftriaxone</b>	100	0	61.2	34.8
<b>Cefalexin</b>	49	51	76.3	23.7
<b>Nalidixic acid</b>	50	50	46.7	53.3
<b>Chloramphenicol</b>	50	50	66.7	33.3
<b>Ciprofloxacin</b>	100	0	61.3	38.7
<b>Clindamycin</b>	0	100	33.3	66.7
<b>Cotrimoxazole</b>	0	100	80	20
<b>Erythromycin</b>	100	0	65.6	34.4
<b>Gentamicin</b>	50	50	87.5	12.5
<b>Nitrofurantoin</b>	0	100	71.4	28.6
<b>Rifampicin</b>	100	0	33.3	76.7
<b>Tetracycline</b>	40	60	22.2	77.8
<b>Ticarcillin</b>	42.9	57.1	9.5	90.5
<b>Tobramycin</b>	55	45	30	70
<b>Vancomycin</b>	60	40	20	80